Cereblon-Mediated Immune Activation for Enhanced Tumor Killing
When markets open on Monday, investors will reassess the competitive landscape in multiple myeloma following pivotal Phase III data showing that a novel cereblon E3 ligase modulator (CELMoD) class, led ... Read More